- Home
- FLO vs ICUI Comparison
FLO vs ICUI Comparison
Compare FLO & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLO
- ICUI
- Stock Information
- Founded
- FLO 1919
- ICUI 1984
- Country
- FLO United States
- ICUI United States
- Employees
- FLO N/A
- ICUI N/A
- Industry
- FLO Packaged Foods
- ICUI Medical/Dental Instruments
- Sector
- FLO Consumer Staples
- ICUI Health Care
- Exchange
- FLO Nasdaq
- ICUI Nasdaq
- Market Cap
- FLO 3.2B
- ICUI 3.2B
- IPO Year
- FLO N/A
- ICUI 1992
- Fundamental
- Price
- FLO $10.53
- ICUI $137.15
- Analyst Decision
- FLO Hold
- ICUI Buy
- Analyst Count
- FLO 4
- ICUI 6
- Target Price
- FLO $15.25
- ICUI $183.60
- AVG Volume (30 Days)
- FLO 4.2M
- ICUI 290.0K
- Earning Date
- FLO 11-06-2025
- ICUI 11-06-2025
- Dividend Yield
- FLO 9.44%
- ICUI N/A
- EPS Growth
- FLO N/A
- ICUI N/A
- EPS
- FLO 0.91
- ICUI N/A
- Revenue
- FLO $5,134,744,000.00
- ICUI $2,320,363,000.00
- Revenue This Year
- FLO $4.26
- ICUI N/A
- Revenue Next Year
- FLO $0.02
- ICUI N/A
- P/E Ratio
- FLO $11.53
- ICUI N/A
- Revenue Growth
- FLO 0.26
- ICUI N/A
- 52 Week Low
- FLO $10.41
- ICUI $107.00
- 52 Week High
- FLO $23.04
- ICUI $175.51
- Technical
- Relative Strength Index (RSI)
- FLO 24.83
- ICUI 62.72
- Support Level
- FLO $10.41
- ICUI $131.99
- Resistance Level
- FLO $12.21
- ICUI $138.48
- Average True Range (ATR)
- FLO 0.35
- ICUI 5.40
- MACD
- FLO -0.08
- ICUI 0.05
- Stochastic Oscillator
- FLO 9.44
- ICUI 62.07
About FLO Flowers Foods Inc.
Flowers Foods Inc is an American company producing bakery food for retail and foodservice across the United States. The product portfolio includes fresh breads, buns, rolls, snack cakes, and tortillas. The company distributes to supermarkets, convenience stores, and restaurants. The key brands are Nature's Own, Wonder, Tastykake, Canyon Bakehouse, DKB.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.